Trials / Completed
CompletedNCT00831077
Early Phase I Microdosing Study of ORM-14540 and ORM-12741
Pharmacokinetic Properties of ORM-14540 and ORM-12741 After Administration of a Microdose of 14C-labelled Drug; An Open, Non-randomised, Single Dose, Single Centre Study in Healthy Male Subjects
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine pharmacokinetic parameters of ORM-12741 and ORM-14540 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORM-14540 | i.v. |
| DRUG | ORM-12741 | i.v. |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-01-28
- Last updated
- 2009-10-08
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00831077. Inclusion in this directory is not an endorsement.